Oregon: OHA dropped the proposed fee increases

Psiconáutica Editorial Team · July 21, 2026

In 2023, Oregon became the first U.S. state to launch a legal program for supervised psilocybin sessions for adults, without the need for a medical diagnosis. Three years later, the Oregon Health Authority (OHA)—the agency managing the program—initiated a regulatory review, subsequently dropped as regards these fees, that proposed the largest fee increase since the program’s inception, a move the industry describes as a tipping point for its economic viability.

What the OHA is proposing

According to documentation from the Rules Advisory Committee, which met between July 6 and July 9, the annual license fee for service centers and psilocybin manufacturers would increase from $10,000 to $20,000 starting in January 2027. The 50% discount currently available to non-profits, veterans, and low-income individuals—which brings the cost to $5,000—would be eliminated, bringing those fees in line with the full rate. The facilitator license fee (for the individual accompanying the sessions) would rise from $2,000 to $4,000 per year, and the associated work permit would increase from $25 to $200. Testing laboratories would also see their fees double, though with a longer lead time: January 2029. Approximately 30% of current licenses utilize some form of discount, all of which would be removed.

Fee funding and sustainability debate

The July report attributed the proposal to insufficient fee revenue against operating costs; that account establishes neither absence of every public funding source nor an audited budget. The July report counted 39 centers that had held a license, about half expired or surrendered, and attributed an estimate of roughly 400 active licenses in total to the industry across centers, manufacturers, facilitators, and laboratories. Ryan Reid, co-founder of the center Bendable Therapy, summarized his concern bluntly: “I don’t think the industry can survive this.” Daniel Huson, director of Rose City Laboratories, noted that the hike “removes any incentive to be a testing lab, because it’s already expensive as it is.” Heidi Pendergast, of the Healing Advocacy Fund, called the increase “unprecedented and disproportionate.” The official schedule sets the revised draft for September 1, a public comment period from September 1 to 21, and virtual hearings on September 15 and 16, prior to a final decision.

What this implies

This article described a July proposal. On September 22, OHA announced it would not adopt those increases; subsequent rulemaking for other changes excludes the fee hikes. However, the Oregon case illustrates a fundamental tension in regulated models for legal access to psychedelic substances in the United States: in the Oregon model described by the July report, reliance on licence-fee revenue creates a sustainability problem when fewer centers operate than anticipated. That interpretation is not an audit of all public funding. This creates a circular dependency that is difficult to resolve when the sector grows more slowly than anticipated. This is not a matter of legality or therapeutic efficacy, but of administrative architecture: how to fund a recognized right of access without turning it, through costs, into a privilege only available to those who can afford it. It is a debate that will likely repeat in other states and countries studying similar regulatory models.

Source

• The Astorian. “‘I don’t think the industry can survive this’: Oregon regulators propose steep psilocybin fee hikes”. The Astorian, July 6, 2026.

Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.